On Monday, TerraForm Power Inc (NASDAQ:TERP)’s shares inclined 1.56% to $31.33.
TerraForm Power Inc (TERP) an owner and operator of clean energy power plants, declared the acquisition of a 9 MW net ownership stake in a portfolio of operating distributed solar power plants from Duke Energy Renewables, a commercial business unit of Duke Energy, the nation’s largest electric power holding company.
Combined with the 23 MW net ownership stake in this portfolio previously acquired from Integrys, TerraForm Power’s total ownership in these 48 plants represents 32 MW. Terms of the Duke sale were not disclosed.
TerraForm Power, Inc. owns and operates solar and wind generation assets serving utility, commercial, and residential customers. As of February 20, 2015, its portfolio compriseed of solar and wind projects located in the United States, Canada, the United Kingdom, and Chile with an aggregate nameplate capacity of 1,507.3 megawatt. The company was formerly known as SunEdison Yieldco, Inc. and changed its name to TerraForm Power, Inc. in May 2014. The company was founded in 2014 and is based in Bethesda, Maryland. TerraForm Power, Inc. is a partner of SunEdison, Inc.
Radian Group Inc (NYSE:RDN)’s shares gained 0.66% to $18.33.
Radian Group Inc. (RDN) stated net income for the quarter ended June 30, 2015, of $50.0 million, or $0.22 per diluted share, which comprised of the following pre-tax items: a loss of $91.9 million on induced conversion and debt extinguishment from recent actions to strengthen the company’s capital structure, and net gains of $28.4 million on investments and other financial instruments. This compares to net income for the quarter ended June 30, 2014, of $174.8 million, or $0.78 per diluted share, which comprised of pre-tax net gains of $25.3 million on investments and other financial instruments, and $71.3 million of net income from suspended operations. The company also stated an income tax provision of $34.8 million for the quarter ended June 30, 2015, contrast to an income tax benefit of $10.7 million for the quarter ended June 30, 2014.
Radian Group Inc., through its auxiliaries, provides mortgage and real estate products and services in the United States. It operates through two segments, Mortgage Insurance, and Mortgage and Real Estate Services (MRES). The Mortgage Insurance segment provides credit-related insurance coverage, principally through private mortgage insurance that protects mortgage lenders from all or a portion of default-related losses on residential mortgage loans made to home buyers, in addition to facilitates the sale of these mortgage loans in the secondary mortgage market. It offers primary mortgage insurance coverage on residential first-liens.
At the end of Monday’s trade, Honeywell International Inc. (NYSE:HON)‘s shares surged dipped -1.08% to $101.66.
Honeywell’s (HON) declared its support of the U.S. Environmental Protection Agency decision to restrict the use of high-global-warming hydrofluorocarbons (HFCs) in a variety of applications counting refrigerants, aerosols and foam insulation blowing agents. These actions will drive adoption of materials with radically lower global warming potentials.
According to the EPA, the projected rule would eliminate an estimated 54 to 64 million metric tons of carbon dioxide equivalent from the atmosphere in 2025. This is the equivalent of removing the carbon dioxide emissions from the annual electricity use of more than 5.8 million homes.
Honeywell International Inc. operates as a diversified technology and manufacturing company worldwide. Its Aerospace segment provides aircraft engines, integrated avionics, systems and service solutions, and related products and services for aircraft manufacturers and operators, airlines, military services, and defense and space contractors; and spare parts, and repair and maintenance services for the aftermarket.
GlaxoSmithKline plc (ADR) (NYSE:GSK), ended its Monday’s trading session with 0.52% gain, and closed at $41.60.
GSK (GSK) declared it has begun shipping FLUARIX® QUADRIVALENT (Influenza Vaccine) doses to US healthcare providers, following licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research.
GSK also has received 2015-16 US license approval for its other quadrivalent flu vaccine FLULAVAL® QUADRIVALENT (Influenza Vaccine). Pending additional FDA lot releases, GSK anticipates to start shipping FLULAVAL® QUADRIVALENT in August. This means that two different presentations of the four-strain vaccines will be accessible to customers. FLUARIX® QUADRIVALENT comes in a 0.5-mL, single-dose, prefilled syringe while FLULAVAL® QUADRIVALENT comes in a 5-mL, multidose vial containing 10 doses (0.5mL each).
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, counting vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, counting respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
